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Good Laboratory Practices and 
Safety Assessments
doi:10.1289/ehp.0900884
Having confidence in scientific procedures 
and data is the sine qua non for determining 
the safety of chemicals and chemical prod-
ucts. For decisions of safety, there must be 
rigorous and thorough application of fun-
damental scientific practices, irrespective of 
the purpose of the study and where it is con-
ducted—academic, industry, or a contract 
laboratory. 
Investigations must be designed and 
conducted by experts; whenever possible, 
standardized and validated test methods and 
test systems should be used, test devices and 
instruments must be appropriately calibrated 
and their accuracy assured, and, most impor-
tant, all of the data, including raw laboratory 
records, should be available for independent 
review. Good Laboratory Practice (GLP) 
requirements, based on these fundamental 
scientific principles and practices, are indis-
pensable for providing scientific confidence 
in studies conducted for chemical safety 
determinations. These reasons explain why 
government agencies worldwide require GLP 
compliance, and why it is entirely appropri-
ate for greater weight to be given to GLP 
studies than non-GLP studies that are only 
available as articles in scientific journals. In 
their commentary Myers et al. (2009) argued 
that non  compliance with GLP should not be 
used as the sole criterion for excluding studies 
from consideration in regulatory decision-
making. We agree that GLP should not be 
the sole criterion, but we strenuously dis-
agree with the authors’ mischaracterization 
of the purpose and function of GLP and with 
their conclusion that GLP has no utility for 
weighting the reliability of studies. 
Evaluating the safety of any substance 
should include review of all relevant stud-
ies utilizing a systematic weight-of-evidence 
framework. Although not all studies that 
are useful for hazard characterization and 
risk assessment may be amenable to GLP 
(e.g., epidemiology and mechanistic stud-
ies, studies conducted before the acceptance 
of current GLP), this does not obviate their 
consideration. Each study, GLP and non-
GLP, should be evaluated and weighed 
in accordance with fundamental scientific 
principles. Factors to be evaluated include 
a) verification of measurement methods and 
data; b) control of experimental variables that 
could affect measurements; c) corroboration 
among studies; d) power (both statistical and 
biological); e) universality of the effects in 
validated test systems using relevant animal 
strains and appropriate routes of exposure; 
f ) biological plausibility of results; and g) uni-
formity among substances with similar attri-
butes and effects. Regulatory agencies [Food 
and Drug Administration (FDA) and U. S. 
Environmental Protection Agency (EPA)] 
and the National Toxicology Program (NTP) 
require studies to be conducted in accordance 
with GLP (FDA 2005; NTP 2006; U.S. EPA 
2007a, 2007b), and the Organisation for 
Economic Co-operation and Development 
(OECD) GLP principles (OECD 1998) 
apply to all OECD member countries.
Academic basic research is very differ-
ent from regulatory research and testing. 
Academic research focuses on developing 
and evaluating new hypotheses, on creat-
ing novel methods, and on discovering new 
findings. Academic research is open to wide 
interpretation and may require significant 
additional studies to clarify and determine 
whether and how broadly the results apply. 
Although novel techniques and discoveries 
of academic investigations stimulate further 
research, they must also stand up to the 
scientific method: hypothesis formulation, 
hypothesis testing, and validation by inde-
pendent replication. Independent replication 
provides critical information on the strength 
of the hypothesis and reliability of test meth-
ods. Inconsistent results can arise from use 
of novel techniques, different test systems, 
uncertainty and differences in test chemi-
cal composition and purity, and a myriad of 
other factors. These facts, in conjunction with 
the more limited availability of actual data 
in most journal publications, means regula-
tory agencies can face significant challenges 
in confirming the quality, performance, or 
data integrity of results obtained solely from 
information available from a typical article 
in peer-reviewed journals. Whereas all study 
records and data from GLP investigations are 
available to agencies, rarely, if ever, are such 
details made available as part of the peer-
review process for publishing a manuscript 
in a scientific journal. This can limit the abil-
ity of an agency to independently evaluate 
conclusions or to conduct alternative analy-
ses of the data. The challenges faced by the 
peer-review procedures of journals have been 
recently highlighted (Nature 2006), and it 
has been pointed out that “…scientists 
understand that peer review per se provides 
only a minimal assurance of quality, and that 
the public conception of peer review as a 
stamp of authentication is far from the truth” 
(Jennings 2006). Journal peer review relies on 
summarization of experi  mental procedures 
and results, and does not include examina-
tion of laboratory study records or raw data. 
The purpose for journal peer review is to 
judge whether the study has been conducted 
and reported according to internationally 
recognized, general scientific standards and 
whether the study meets the interest level for 
dissemination to scientific community. It is 
not designed to provide assurance of accu-
racy or to recalculate raw data, and it does 
not provide an opportunity for independent 
audit of the study. Myers et al. (2009) failed 
to clearly make these distinctions. 
Relevant internationally agreed test   
methods are used by industry to generate tox-
icity data for safety determinations by regula-
tory agencies. Incorporation of GLP in these 
laboratory tests assures that written protocols 
and standard operating procedures for each 
study component are developed and carefully 
and completely followed. GLP also requires 
meticu  lous adherence to dosing techniques; 
the use of adequate group sizes to allow mean-
ingful statistical analysis; charac  terization 
(identity, purity, concentration) of test and 
control substances, including dosing solutions; 
detailed recording of study measurements and 
data; and collection of all raw laboratory data 
in a manner that can be retained and made 
available for regulatory agencies to audit and 
reach independent conclusions. Quality con-
trol procedures, quality assurance reviews, and 
facility inspections are also used to monitor 
and enforce GLP compliance. The relevance, 
reliability, sensitivity, and specificity of most 
test methods required of industry by regula-
tory agencies are well understood because they 
have been subjected to extensive, round-robin 
validation programs conducted in numerous 
laboratories throughout the world. This high 
level of scientific rigor, in conjunction with 
the detailed processes of GLP, provides regu-
latory agencies increased confidence in both 
the relevance and quality of GLP scientific 
studies for safety decisions, and it is the reason 
it is wholly appropriate in regulatory decision 
making for greater weight and confidence to 
be afforded to studies conducted in accor-
dance with GLP. 
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with the peer- and administrative-review 
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views expressed here are those of the authors 
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We are in complete agreement with the 
statement by Becker et al. that “having con-
fidence in scientific procedures and data is 
the sine qua non for determining the safety 
of chemicals and chemical products.” Our 
aim in writing the commentary (Myers et al. 
2009) was not to challenge the original 
intent of Good Laboratory Practices (GLP) 
requirements, which was to establish stan-
dards of record keeping in contract labora-
tory research so as to reduce the likelihood 
of fraud. Our goal instead was to show—
through an analysis of the application of 
GLP data on bisphenol A (BPA) in regu-
latory proceedings—that GLP by itself is 
insufficient to guarantee valid and reliable 
science. Becker et al. appear to have missed 
the point of our commentary entirely. 
In the case of BPA, three GLP studies 
have been offered by industry-sponsored 
laboratories as proof of the chemical’s safety 
(Cagen et al. 1999; Tyl et al. 2002, 2008). 
Each has errors in study design and/or data 
interpretation that are sufficiently serious as 
to invalidate the conclusions of these studies 
(Myers et al. 2009). Nevertheless, because the 
studies were conducted using GLP guidelines, 
they were judged by regulators as being more 
reliable than the many National Institutes 
of Health (NIH)-funded and peer-reviewed 
studies that have reported adverse effects 
(Richter et al. 2007; vom Saal et al. 2007). 
As our commentary (Myers et al. 2009)
clearly establishes, GLP did not guaran-
tee the scientific validity of these three stud-
ies. Because previous analyses had identified 
serious flaws in the first two of those GLP 
studies, we focused critical attention on the 
most recent (Tyl et al. 2008), which both the 
European Food Safety Authority (EFSA 2006) 
and the U.S. Food and Drug Administration 
(FDA) had identified as key in their BPA risk 
assessments (FDA 2008). We found three 
main flaws: a) the animals were inexplicably 
insensitive to estrogen; b) the assays were out-
dated and insensitive compared with methods 
used in NIH-funded research showing adverse 
effects; and c) validity of the findings was chal-
lenged. For example, the prostate weights of 
control animals reported by Tyl et al. (2008) 
were > 70% larger (mean, > 72 mg) than those 
reported by numerous laboratories, includ-
ing a previously published study using CD-1 
mice [conducted at RTI, where the study by 
Tyl et al. (2008) was conducted] that reported 
mean prostate weights of 46 mg in CD-1 
males that were examined at a similar age 
(Heindel et al. 1995).
Since we published our commentary 
(Myers et al. 2009), a possible contributor 
to both the estrogen insensitivity and the 
enlarged control prostates has been suggested: 
Approximately 3 years before the experiments 
that formed the basis of the study by Tyl et al. 
(2008), there was a polycarbonate fire that 
released BPA into the RTI laboratory where 
the research was conducted (Kissinger and 
Rust 2009). An investigation revealed that 
animals in the laboratory were exposed to low 
doses of BPA that government-funded sci-
ence (Richter et al. 2007) indicates could affect 
research animals.
Additional uncertainties about Tyl et al.’s 
study (Tyl et al. 2008) have now been iden-
tified by the lead author. Whereas the pub-
lished paper reports that the animals were 
examined at approximately 14 weeks of age, 
Tyl testified at an FDA hearing in September 
2008 that they were 6 months of age, and 
then at a German Environmental Protection 
Agency hearing in March 2009 that they were 
5 months of age (Kissinger and Rust 2009). 
There she confirmed that the information in 
the original article was inaccurate. Because an 
animal’s physiology changes as it ages, these 
contradictory statements are problematic for 
all reported outcomes; even at 5–6 months 
of age, normal, healthy CD-1 male mice 
would not have the grossly enlarged prostates 
reported by Tyl et al. (2008).
The use of flawed science, however, is not 
the only concern. The type of multi  generation 
testing approach used in these studies is, quite 
simply, insufficient for the testing of endo-
crine-disrupting chemicals. This is not a new 
concept. The need for more specific tests for 
endocrine-active compounds led in 1998 to 
the establishment at the U.S. Environmental 
Protection Agency (U.S. EPA) of the 
Endocrine Disruptor Screening Program, 
mandated by Congress (U.S. EPA 1998). 
After virtually no progress for over a decade, 
in 2009 the U.S. EPA finally announced a set 
of testing procedures that will be examined. 
The proposed “new” methodology, heavily 
dependent upon traditional toxicologic meth-
ods used in multi  generational GLP studies, is 
still woefully inadequate (Colborn 2009). 
The letter by Becker et al. provides a strik-
ing example of the reluctance of industry lob-
byists to hear this message. In the eyes of the 
36 scientific colleagues who co  authored our 
commentary (Myers et al. 2009), the BPA 
studies that Becker et al. attempt to defend 
are so seriously flawed as to be indefensible. 
Rather than continue to defend a dead issue, 
we encourage industry representatives to come 
into the 21st century and help us devise new 
paradigms for testing endocrine-disrupting 
chemicals that will safeguard human health. 
The authors’ freedom to design, conduct, 
interpret, and publish this letter was not nor is 
compromised by any controlling sponsor as a con-
dition of review and publication.
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Electromagnetic Fields and the 
Precautionary Principle
doi:10.1289/ehp.0901111
Since Galileo, debates in science are sup-
ported by logical reasoning and reference to 
statements of fact and not by reference to 
“authorities.” Consequently, litera  ture serves 
or should serve two purposes: to give credit 
to thoughts expressed earlier by others, and 
to refer to statements of facts.
The article by Dolan and Rowley (2009)— 
employees of the mobile telephone indus-
try—is an example of a compilation of points 
of views expressed by authorities. No num-
ber of references to authoritative statements 
can replace scientific discourse. The article 
can be summarized as follows: There is no 
convincing evidence of harm from exposure 
to microwaves below levels recommended 
by the International Commission on Non-
Ionizing Radiation Protection (ICNIRP) 
(1998); therefore, there is no harm, and 
hence application of the precautionary prin-
ciple is not indicated. 
Indeed, the precautionary principle is not 
intended as a response to unfounded fears 
of the public or to aim at zero risk, but as a 
risk management strategy in case of scientific 
uncertainty about the existence or magni-
tude of a risk. Apparently Dolan and Rowley 
(2009) are not aware that their subjective rea-
soning does not differ from the unfounded 
fears of the public and can be summarized as 
“unfounded reassurance of no harm.”
In principle, ethical considerations, value 
judgments, and consensus play an important 
role when giving guidance to public health 
policy. This is because “it is impossible to 
derive . . . a proposal for a policy from a sen-
tence stating a fact” (Popper 1945). Use of 
subjective terms such as “sufficient evidence” 
(let alone “convincing evidence”— convincing 
for whom?) or “adverse effect” is unavoidable. 
Referring to the World Health Organization 
(WHO 2000), Dolan and Rowley (2009) 
stated: “The corresponding advice to govern-
ments is to adopt science based guidelines and 
not to undermine confidence by incorporat-
ing additional arbitrary safety factors.” The 
expression “science-based guidelines,” if taken 
literally, is a contradiction in terms. Although 
public health guidelines should be based on a 
thorough risk assessment, neither the assess-
ment itself nor the reasoning that is applied 
to derive a guideline can be scientific. No sci-
entific evidence can define a margin of safety; 
no scientific evidence can replace the value 
judgment of which evidence to rely on, which 
evidence to dismiss, and so forth. Safety fac-
tors are always—at least to certain degree—
arbitrary. For example, we very rarely have 
scientific evidence about the distribution of 
sensitivity to a toxic agent in the population; 
therefore, we apply arbitrary factors for taking 
inter  individual differences into account. What 
is important, and nearly always neglected in 
the area of electromagnetic fields (EMF), is to 
clearly state where value judgments and arbi-
trary decisions entered the argument and the 
derivation of guidelines. 
The international standards for EMF 
(ICNIRP 1998; IEEE 2006) are based on 
immediate effects of exposure, such as excita-
tion of nerve or muscle cells for low-frequency 
fields and increase of body tempera  ture for 
high-frequency fields, not because there are 
no other effects, even at levels far below the 
guideline levels derived from these acute 
effects, but because the panels came to the 
consensus that these other effects cannot (yet) 
form the basis for the derivation of guidelines. 
For example, the International Agency for 
Research on Cancer (IARC 2002) classified 
power frequency magnetic fields as a possible 
human carcino  gen. In that case, the subjec-
tivity of the assessment is fully trans  parent: 
The basic rules of IARC were violated, as the 
panel questioned whether epidemiologic evi-
dence can be causally interpreted in spite of 
evidence that neither bias nor confounding 
accounts for the increased childhood leuke-
mia risk. The exposure level for which there is 
evidence of an increased childhood leukemia 
risk is far below the international standards, 
but the panels setting the standard did not 
use this evidence as a basis for the deriva-
tion of a guideline level for power frequency 
fields. There are surely many arguments for 
this decision. However, none are scientific. 
This is not meant as a reproach, because we 
recog  nize the fact that guidelines cannot be 
derived from scientific statements alone. 
It would be much more appropriate if 
Dolan and Rowley expressly stated that they 
are completely satis  fied with the interna-
tional standards and that the industry does 
not want to be bothered by allusions to 
precaution.Correspondence
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EMF and the Precautionary 
Principle: Dolan and Rowley 
Respond
doi:10.1289/ehp.0901111R
In their letter commenting on our article 
(Dolan and Rowley 2009), Kundi et al.
attempt to discredit us as “employees of the 
mobile telephone industry” and imply that we 
are merely advocating an industry position of 
support for the international radio  frequency 
exposure guidelines rather than addressing 
issues of substance regarding the application 
of the precautionary principle to mobile tele-
phony. A careful reading of our article clearly 
demonstrates this is not the case.
With few exceptions, countries around 
the world have implemented the inter-
national guidelines based on many scientific 
reviews undertaken by experts appointed by 
national governments over the past decade. 
Kundi et al. simply ignore these reviews 
and their conclusions because they do not 
agree with them. Although Kundi et al. are 
entitled to hold and promulgate their own 
views, they should acknowledge that they 
are acting as advocates for lower guidelines 
(based on their own subjective analysis of 
existing scientific evidence) and they should 
not simply dismiss anyone who does not 
agree with their point of view.
Kundi et al. seem to think that the 
precautionary principle should be applied 
whenever there is some scientific doubt or 
uncertainty, without recognizing that its use 
is limited by national regulatory and legal 
constraints, which we addressed in our 
commentary (Dolan and Rowley 2009). 
In particular, the concerns should be plau-
sible (World Commission on the Ethics of 
Scientific Knowledge and Technology 2005). 
As an example, the European Court of First 
Instance (Pfizer Animal Health SA v. Council 
of the European Union 2002) has ruled that
[A] preventive measure cannot properly be 
based on a purely hypothetical approach to the 
risk, founded on mere conjecture which has not 
been scientifically verified . . . . [A] preventive 
meas  ure may be taken only if the risk, although 
the reality and extent thereof have not been fully 
demonstrated by conclusive scientific evidence, 
appears nevertheless to be adequately backed up 
by the scientific data available at the time when 
the measure was taken.
The many scientific review bodies we 
referred to in our article (Dolan and Rowley 
2009) have not considered the existing health 
data on mobile telephony adequate to trigger 
the application of the precautionary principle.
We accept that decisions regarding 
application of the precautionary princi-
ple are not to be made by scientists alone 
because they “have neither democratic 
legitimacy nor political responsibilities” 
(Pfizer Animal Health SA v. Council of the 
European Union 2002). However, govern-
ments should not simply disregard scien-
tific advice or adopt popularist policies and 
“fall prey to public fear when it is baseless” 
(Telstra Corporation Limited v. Hornsby 
Shire Council 2006).
In the conclusion of our commentary 
(Dolan and Rowley 2009), we made it clear 
that there are many things that governments 
and industry can do to better address pub-
lic concern, including supporting ongoing 
research and conducting education and 
information programs for the public who, 
when fully informed, are better able to take 
their own personal precautionary measures if 
they wish to do so. What should be avoided 
is the rush to adopt measures—justified by 
reference to the precautionary principle—to 
reassure the public, because this has been 
shown to actually increase public concern 
(Weidemann and Schutz 2005). 
The views expressed in this paper are those 
of the authors and do not necessarily represent 
the views of any organizations or companies 
with which they are professionally associated. 
Their freedom to design, conduct, interpret, 
and publish research is not compromised by 
any controlling sponsor as a condition of review 
and publication.
Both authors are employed by trade associa-
tions representing the mobile communications 
industry. 
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